← Back to Search

DD-CA for Type 2 Diabetes

Phase 3
Waitlist Available
Led By Athena Philis-Tsimikas, MD
Research Sponsored by Scripps Whittier Diabetes Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90-days, 180-days
Awards & highlights

Study Summary

This study is evaluating whether a digital intervention can help improve glucose control and lower transmission of the flu in Hispanic and Latino populations.

Eligible Conditions
  • Type 2 Diabetes
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90-days, 180-days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90-days, 180-days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days
Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 90 Days
Hospital Readmission Rate Within 30 Days of Discharge
Secondary outcome measures
COVID-19 Patient Survey (Phenix Toolkit) Within 180 Days of Discharge
COVID-19 Patient Survey (Phenix Toolkit) Within 90 Days of Discharge
Diabetes Distress Scale - Change From Baseline to 180 Days
+14 more
Other outcome measures
Readmission Rate

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DD-CAExperimental Treatment1 Intervention
In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
Group II: Usual Care (UC)Active Control1 Intervention
UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hospital: DD-CA
2021
Completed Phase 3
~180

Find a Location

Who is running the clinical trial?

Scripps Whittier Diabetes InstituteLead Sponsor
17 Previous Clinical Trials
5,217 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,350 Previous Clinical Trials
4,314,630 Total Patients Enrolled
Athena Philis-Tsimikas, MDPrincipal Investigator - Scripps Whittier Diabetes Institute
Scripps Whittier Diabetes Institute
13 Previous Clinical Trials
4,487 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
Athena Philis-Tsimikas 2021. "Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04591015.
~41 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top